中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

4 records (took 0.008 seconds)

    NOVEL COPOLYMERS AND THEIR USE IN PHARMACEUTICAL DOSAGE FORMS
    1.
    发明公开
    NOVEL COPOLYMERS AND THEIR USE IN PHARMACEUTICAL DOSAGE FORMS 审中-公开

    公开(公告)号：US20230257501A1

    公开(公告)日：2023-08-17

    申请号：US18014508

    申请日：2021-07-02

    Applicant: BASF SE

    Inventor： Theo Smit ,  Ferdinand Paul Brandl ,  Felicitas Guth ,  Karl Kolter ,  Frank Schmidt

    IPC: C08F226/10 ,  C08F2/06 ,  A61K9/16

    CPC classification number: C08F226/10 ,  C08F2/06 ,  A61K9/1635

    Abstract: Copolymer, wherein structural units are derived from: i) an acrylic carboxylic acid monomer (4 to 18% by weight), selected from the group consisting of acrylic acid and methacrylic acid, ii) a 5 hydrophobic methacrylate (more than 8% by weight), selected from a group consisting of isopropyl methacrylate, tert-butyl methacrylate and cyclohexyl methacrylate, iii) a N-vinyl lactam, selected from a group consisting of N-vinyl pyrrolidone and N-vinylcaprolactam and optionally iv) 2-hydroxyethyl methacrylate, with the proviso that the total amount of structural units derived from the monomer groups adds up to 100% by weight, and the calculated solubility parameter SP of 10 the copolymer is between 22.0 and 25.0 MPa1/2, and the use of the copolymers as crystallization inhibitors in pharmaceutical dosage forms for inhibiting the recrystallization of an active ingredient in an aqueous environment of a human or animal body.

    NOVEL TERPOLYMERS AND THEIR USE IN PHARMACEUTICAL DOSAGE FORMS
    2.
    发明申请
    NOVEL TERPOLYMERS AND THEIR USE IN PHARMACEUTICAL DOSAGE FORMS 有权

    公开(公告)号：US20210069112A1

    公开(公告)日：2021-03-11

    申请号：US16772273

    申请日：2018-12-07

    Applicant: BASF SE

    Inventor： Ferdinand Paul Brandl ,  Theo Smit ,  Felicitas Guth ,  Karl Kolter ,  Maximilian Angel ,  Frank Schmidt

    IPC: A61K9/16 ,  C08F220/18 ,  A61K47/32 ,  A61K31/635 ,  A61K31/58 ,  A61K31/216 ,  A61K31/5377

    Abstract: Terpolymer, wherein 20 to 35% by weight of the structural units are derived from acrylic acid, 45 to 60% by weight of the structural units from a hydrophobic methacrylate selected from a group consisting of isopropyl methacrylate, tert-butyl methacrylate and cyclohexyl methacrylate and 15 to 40% by weight of the structural units from a third olefinic monomer selected from the group consisting of N-vinyl lactam, hydroxy ethyl methacrylate and phenoxyethyl acrylate with the proviso that the total amount of structural units derived from the three monomer groups adds up to 100% by weight, and the use of the terpolymers as crystallization inhibitors in pharmaceutical dosage forms for inhibiting the recrystallization in an aqueous environment of a human or animal body of an active ingredient.

Patent Agency Ranking